Statins: Putting the benefit/risk into perspective

International Journal of Clinical Practice, Supplement

Volumn , Issue 137, 2003, Pages 27-33

  Shepherd, James ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL DISCOMFORT; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ASTHENIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; FLU LIKE SYNDROME; HEADACHE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MALAISE; META ANALYSIS; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOSIS; VERTIGO;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RHABDOMYOLYSIS; RISK ASSESSMENT;

EID: 0242596593     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. WHO. World Health Report 2002. Geneva: World Health Organization, 2002.
2. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, Tex.: American Heart Association, 2002.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-2828.
5. Petersen S, Peto V, Rayner M. Coronary Heart Disease Statistics 2003. Oxford, UK: British Heart Foundation Health Promotion Research Group, 2003.
6. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
7. Alberts MJ. Suppression of recurrent transient ischemic attacks by a statin agent. Neurology 2001; 56: 531-532.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
9. Shepherd J, Cobbs SM, Ford IT et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
10. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-1009.
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
12. Downs JR, Clearfield M, Tyroler HA et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87: 1074-1079.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
14. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
15. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT - LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
16. Pfeffer MA, Sacks FM, Moye LA et al. Cholesterol And Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995; 76: 98C-106C.
17. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
18. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-540.
19. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
20. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
21. Brewer HB. Benefit-risk assessment of rosuvastatin 10 to 40 mg. Am J Cardiol 2003; 92(4A): 23-29.
22. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917.
23. Fuhrmans V. Bayer discloses higher death toll from Baycol. Wall Street Journal, Jan 21, 2002. A10.
24. Pasternak RC, Smith SC, Bairey-Marz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-1028.
25. Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-564.
26. Gaist D, Rodriguez LA, Huerta C et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565-569.
27. Dedier J, Stampfer MJ, Hankinson SE et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002; 40: 604-608.
28. Appleby PN, Davey GK, Key TJ. Hypertension and blood pressure among meat eaters, fish eaters, vegetarians and vegans in EPIC-Oxford. Public Health Nutr 2002; 5: 645-654.
29. Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed". BMJ 2000; 320: 503-506.
30. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.